Detalhe da pesquisa
1.
Author Correction: HER kinase inhibition in patients with HER2- and HER3-mutant cancers.
Nature
; 566(7745): E11-E12, 2019 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-30755741
2.
A Phase I Dose-Escalation Study of LY3405105, a Covalent Inhibitor of Cyclin-Dependent Kinase 7, Administered to Patients With Advanced Solid Tumors.
Oncologist
; 29(1): e131-e140, 2024 Jan 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-37531083
3.
The phase I/II eNRGy trial: Zenocutuzumab in patients with cancers harboring NRG1 gene fusions.
Future Oncol
; 2024 Feb 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-38348690
4.
HER kinase inhibition in patients with HER2- and HER3-mutant cancers.
Nature
; 554(7691): 189-194, 2018 02 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-29420467
5.
NTRK1 Fusions identified by non-invasive plasma next-generation sequencing (NGS) across 9 cancer types.
Br J Cancer
; 126(3): 514-520, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34480094
6.
Contribution of clonal hematopoiesis to adult-onset hemophagocytic lymphohistiocytosis.
Blood
; 136(26): 3051-3055, 2020 12 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-32961550
7.
Clinical implications of drug-induced liver injury in early-phase oncology clinical trials.
Cancer
; 126(22): 4967-4974, 2020 11 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-32809222
8.
Basket Studies: Redefining Clinical Trials in the Era of Genome-Driven Oncology.
Annu Rev Med
; 69: 319-331, 2018 01 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-29120700
9.
A phase Ib dose-escalation and expansion study of the oral MEK inhibitor pimasertib and PI3K/MTOR inhibitor voxtalisib in patients with advanced solid tumours.
Br J Cancer
; 119(12): 1471-1476, 2018 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-30425349
10.
Precision oncology: Charting a path forward to broader deployment of genomic profiling.
PLoS Med
; 14(2): e1002242, 2017 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-28222135
11.
How I treat hemophagocytic lymphohistiocytosis in the adult patient.
Blood
; 125(19): 2908-14, 2015 May 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-25758828
12.
Marked hyperferritinemia does not predict for HLH in the adult population.
Blood
; 125(10): 1548-52, 2015 Mar 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-25573993
13.
Haemophagocytic lymphohistiocytosis in adults: a multicentre case series over 7 years.
Br J Haematol
; 172(3): 412-9, 2016 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-26537747
14.
Niraparib in Recurrent Ovarian Cancer.
N Engl J Med
; 376(8): 801, 2017 02 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-28229583
15.
Convergent evolution of BRCA2 reversion mutations under therapeutic pressure by PARP inhibition and platinum chemotherapy.
NPJ Precis Oncol
; 8(1): 34, 2024 Feb 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-38355834
16.
Discovery and Clinical Proof-of-Concept of RLY-2608, a First-in-Class Mutant-Selective Allosteric PI3Kα Inhibitor That Decouples Antitumor Activity from Hyperinsulinemia.
Cancer Discov
; 14(2): 240-257, 2024 Feb 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37916956
17.
Avelumab Plus Talazoparib in Patients With Advanced Solid Tumors: The JAVELIN PARP Medley Nonrandomized Controlled Trial.
JAMA Oncol
; 9(1): 40-50, 2023 01 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36394849
18.
Avelumab Plus Talazoparib in Patients With BRCA1/2- or ATM-Altered Advanced Solid Tumors: Results From JAVELIN BRCA/ATM, an Open-Label, Multicenter, Phase 2b, Tumor-Agnostic Trial.
JAMA Oncol
; 9(1): 29-39, 2023 01 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36394867
19.
RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity across FGFR2 Alterations and Resistance Mutations.
Cancer Discov
; 13(9): 2012-2031, 2023 09 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-37270847
20.
Reversion mutations in germline BRCA1/2-mutant tumors reveal a BRCA-mediated phenotype in non-canonical histologies.
Nat Commun
; 13(1): 7182, 2022 11 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-36418296